Daraxonrasib
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
Pancreatic cancer: New drug extends lives but isn't a cure
Pancreatic cancer: New drug extends lives but isn't a cure June 8, 2026Pancreatic cancer is notoriously difficult to treat — and in many cases leads to death just months after diagnosis. So it is no surprise that this headline created a stir: In a recent study, a new drug, daraxonrasib, was able to double the survival time of patients with pancreatic cancer. Compared with patients who underwent chemotherapy, those treated with daraxonrasib not only lived longer, but also reported a better...
After new drug’s ‘unprecedented’ results for pancreatic cancer, doctors look at other uses
Every single patient with advanced pancreatic cancer who walked into Dr. Zev Wainberg’s office told him they would rather take an experimental medication than endure another round of chemotherapy. Wainberg, co-director of UCLA Health’s GI Oncology Program, was leading a clinical trial of a new drug called daraxonrasib. All the study participants previously had chemotherapy that was starting to fail.
Pancreatic cancer: New drug results prompt standing ovation at oncology conference
A new drug for advanced pancreatic cancer is being hailed as a major breakthrough after trial results showed that it almost doubles survival time in patients previously treated with chemotherapy. Phase 3 trial results for daraxonrasib, a once daily oral treatment, have been described as a potential “revolution” in treating pancreatic cancer, which has the lowest survival of all common cancers, with five year survival less than 7%.In the RASolute 302 trial of 500 patients with metastatic...
Daily pill doubles survival time for pancreatic cancer patients
The drug, daraxonrasib, has been hailed as a breakthrough in managing the deadliest of all the major cancers.
The Happy Pod: Kinder medicine for millions of cancer patients
A new DNA test can distinguish between patients who are likely to benefit from chemotherapy and those who are not, meaning many with the most common form of breast cancer can avoid the brutal treatment. Also, scientists have found a daily pill that could double the survival time for people with advanced pancreatic cancer. Daraxonrasib appears to be a breakthrough in managing a disease that has the highest mortality rate of all major cancers.
Daily pill doubles survival time for pancreatic cancer patients
The drug, daraxonrasib, has been hailed as a breakthrough in managing the deadliest of all the major cancers.
Daily pill doubles survival time for pancreatic cancer patients
The drug, daraxonrasib, has been hailed as a breakthrough in managing the deadliest of all the major cancers.
Daily pill can double survival time for world’s deadliest cancer, trial shows
Experts hail daraxonrasib as ‘gamechanger’ for patients with advanced pancreatic cancerA daily pill can double survival time in patients with the world’s deadliest cancer, according to the results of a clinical trial that experts are saying is a “gamechanger” and one of the biggest breakthroughs in decades. Currently, there are few treatments for pancreatic cancer, and most do little or nothing to help. For decades, scientists have worked relentlessly trying to find clever solutions for a...
Daily pill doubles survival time for pancreatic cancer patients
The drug, daraxonrasib, has been hailed as a breakthrough in managing the deadliest of all the major cancers.
Daily pill doubles survival time for pancreatic cancer patients
The drug, daraxonrasib, has been hailed as a breakthrough in managing the deadliest of all the major cancers.